Key facts: SMMT Seeks Financing; Shares Jump on AstraZeneca Pact

AstraZeneca and HUTCHMED submitted a U.S. New Drug Application for savolitinib plus Tagrisso in EGFR-mutated lung cancer with MET changes. The combination is not yet approved in the U.S. The application is based on the SAFFRON trial, which showed statistically significant improvements in progression-free and overall survival compared to chemotherapy. The FDA has not announced whether it will review the application or set a decision date.

AstraZeneca (AZN) advances elecoglipron, a once-daily GLP-1 pill, into Phase 3 trials for obesity and type 2 diabetes. Medicare's Bridge program covers 700,000 seniors for GLP-1 treatments, with 70% using Eli Lilly (LLY) products. Elecoglipron's Medicare coverage and pricing remain uncertain, pending FDA approval and CMS decisions.

Summit Therapeutics (SMMT) shares rose 5.74% to $17.32 on Wednesday after AstraZeneca agreed to invest $2 billion in convertible preferred shares, implying a $18.36 common stock price. The deal funds clinical trials for ivonescimab, a potential cancer treatment, and includes a collaboration to study its combination with AstraZeneca's Sone-Ve. The investment is expected to close within a week, subject to regulatory approvals.

AstraZeneca (LSE: AZN) filed a US New Drug Application for a lung cancer treatment combination, highlighting its oncology pipeline. The company's share price fell 15.53% over 90 days but is up 0.43% over one year. Analysts estimate a fair value of £159.11, suggesting the stock is undervalued at its current £122.80. Management projects $10+ billion in peak revenue from new medicines, but faces risks from blockbuster drug reliance and pricing competition.

AstraZeneca (AZN) will invest $2B in Summit Therapeutics (SMMT) via preferred stock convertible at $18.36/share, a 18.6% premium to Summit's prior close. Summit shares rose 5.88% on the news. The deal includes a trial collaboration but no licensing rights. Summit has no revenue, and its value hinges on ivonescimab, its sole drug. Citi raised its target to $43, citing validation of ivonescimab. The FDA decision on ivonescimab is due by November 2026.

AstraZeneca (AZN) invested $2B in Summit Therapeutics (SUM) for cancer drug development. Novo Nordisk (NVO) agreed to a $2.6B deal with Jiangsu Hengrui (600276) for an anti-obesity pill. Eli Lilly (LLY) claims its anti-obesity drug outperforms NVO's Ozempic. AZN, NVO, and 600276 saw minor stock movements; SUM surged 8%.